Wesbanco Bank Inc. lessened its holdings in shares of Allergan plc (NYSE:AGN) by 12.1% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 19,973 shares of the company’s stock after selling 2,742 shares during the quarter. Wesbanco Bank Inc.’s holdings in Allergan were worth $3,330,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of AGN. Kaizen Advisory LLC boosted its position in shares of Allergan by 156.2% during the 2nd quarter. Kaizen Advisory LLC now owns 830 shares of the company’s stock valued at $138,000 after acquiring an additional 506 shares during the last quarter. Migdal Insurance & Financial Holdings Ltd. boosted its position in shares of Allergan by 3,193.3% during the 2nd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 988 shares of the company’s stock valued at $165,000 after acquiring an additional 958 shares during the last quarter. Avestar Capital LLC boosted its position in shares of Allergan by 46.1% during the 1st quarter. Avestar Capital LLC now owns 1,185 shares of the company’s stock valued at $183,000 after acquiring an additional 374 shares during the last quarter. Aries Wealth Management bought a new stake in shares of Allergan during the 2nd quarter valued at about $202,000. Finally, Parallel Advisors LLC boosted its position in shares of Allergan by 34.9% during the 2nd quarter. Parallel Advisors LLC now owns 1,233 shares of the company’s stock valued at $205,000 after acquiring an additional 319 shares during the last quarter. Hedge funds and other institutional investors own 78.87% of the company’s stock.

Shares of NYSE AGN traded down $0.77 during trading hours on Tuesday, reaching $189.98. 102,971 shares of the stock traded hands, compared to its average volume of 1,845,747. The stock has a market cap of $63.00 billion, a price-to-earnings ratio of 11.62, a P/E/G ratio of 1.39 and a beta of 1.16. The company has a current ratio of 1.00, a quick ratio of 0.85 and a debt-to-equity ratio of 0.34. Allergan plc has a 52-week low of $142.81 and a 52-week high of $237.41.

Allergan (NYSE:AGN) last announced its quarterly earnings data on Thursday, July 26th. The company reported $4.42 earnings per share for the quarter, beating the Zacks’ consensus estimate of $4.13 by $0.29. The company had revenue of $4.10 billion for the quarter, compared to analysts’ expectations of $3.92 billion. Allergan had a positive return on equity of 8.60% and a negative net margin of 10.29%. Allergan’s revenue for the quarter was up 2.3% compared to the same quarter last year. During the same period last year, the firm posted $4.02 EPS. analysts forecast that Allergan plc will post 16.29 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Monday, September 17th. Investors of record on Friday, August 17th will be issued a dividend of $0.72 per share. The ex-dividend date of this dividend is Thursday, August 16th. This represents a $2.88 dividend on an annualized basis and a dividend yield of 1.52%. Allergan’s dividend payout ratio is 17.61%.

A number of brokerages have recently issued reports on AGN. Zacks Investment Research upgraded Allergan from a “hold” rating to a “buy” rating and set a $197.00 price target for the company in a research report on Wednesday, July 11th. Mizuho reiterated a “hold” rating and set a $150.00 price target on shares of Allergan in a research report on Wednesday, May 30th. Cantor Fitzgerald set a $180.00 price target on Allergan and gave the company a “hold” rating in a research report on Thursday, July 19th. Argus reiterated a “hold” rating on shares of Allergan in a research report on Thursday, July 5th. Finally, Bank of America dropped their price target on Allergan from $213.00 to $209.00 and set a “buy” rating for the company in a research report on Tuesday, May 1st. Two analysts have rated the stock with a sell rating, six have issued a hold rating and seventeen have issued a buy rating to the company. Allergan currently has an average rating of “Buy” and an average target price of $209.48.

Allergan Company Profile

Allergan plc, a specialty pharmaceutical company, develops, manufactures, markets, and distributes medical aesthetics, biosimilar, and over-the-counter pharmaceutical products worldwide. It operates through US Specialized Therapeutics, US General Medicine, and International segments. The company offers a portfolio of products that provide treatment for the central nervous system, gastroenterology, women's health and urology, ophthalmology, neurosciences, medical aesthetics, dermatology, plastic surgery, liver disease, inflammation, metabolic syndromes, and fibrosis, as well as Alzheimer's disease.

See Also: Price to Earnings Ratio (PE), For Valuing Stocks

Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan plc (NYSE:AGN).

Institutional Ownership by Quarter for Allergan (NYSE:AGN)

Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.